Aprea Therapeutics (NASDAQ:APRE) Trading Down 2.5% – Time to Sell?

Aprea Therapeutics, Inc. (NASDAQ:APRE) shares fell 2.5% on Tuesday . The company traded as low as $0.65 and last traded at $0.6520. Approximately 43,647 shares were traded during mid-day trading, a decline of 33% from the average daily volume of 65,580 shares. The stock had previously closed at $0.6690.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on APRE shares. HC Wainwright decreased their price target on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Wedbush reduced their price objective on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday. Finally, Oppenheimer started coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 target price for the company. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Aprea Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.07.

Aprea Therapeutics Stock Down 2.5%

The company has a market capitalization of $8.07 million, a PE ratio of -0.42 and a beta of 1.50. The company has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $0.80.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. As a group, equities analysts anticipate that Aprea Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.

Institutional Trading of Aprea Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of APRE. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics in the fourth quarter worth $40,000. DRW Securities LLC bought a new stake in Aprea Therapeutics during the fourth quarter valued at $103,000. Finally, AIGH Capital Management LLC grew its position in Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares in the last quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.